Opinion

HIV activists are essential to the COVID-19 response

27 Nov 2020

News Opinion

The legacy of HIV activism is approaching a 40-year history, one which is inextricably linked with the actions of pharmaceutical...

COVID-19 & TB: Why whether you live or die is a matter of justice, not science

22 Oct 2020

Opinion

Johnson & Johnson, a brand built on images of happy gurgling babies and the tagline ‘no more tears’, has the...

New money for old drugs: COVID-19 is not a profit-making opportunity

30 Jul 2020

Opinion

To try to limit the catastrophic impact of COVID-19, a huge amount of funding has been invested into scientific development...

Indonesia: Community action results in cheaper HIV treatment

27 Feb 2020

News Opinion

First published by The Jakarta Post. Indonesia has an increasing rate of new HIV infections, with approximately 46,000 people newly...

We can’t end AIDS without tackling patent abuse

25 Jan 2020

News Opinion

Despite significant scientific advancements for HIV, along with global and national commitments to ‘end AIDS’, hundreds of thousands of people...

TEDWomen: Why are drug prices so high?

24 Jan 2020

News Opinion

Hear from I-MAK’s Priti Krishtel on how the outdated patent system is the hidden reason that drug prices are so high...

The problem with patents: Commitments to HIV and universal health coverage are being undermined in middle-income countries

23 Sep 2019

News Opinion Research

A joint blog by Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC),...

Brazilian Health Minister’s speech on compulsory licenses exposes a disconnect with the world

7 Aug 2019

News Opinion

Adapted from a story first published by GTPI. Compulsory licensing is a vital public policy tool to combat the high...

Still an avoidable tragedy: Brazil’s view on the EU-Mercosur free-trade agreement

2 Jul 2019

News Opinion

The signing of the Free Trade Agreement (FTA) between Mercosur and the European Union on 28 June 2019, means that...

Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!

2 Jul 2019

Opinion

Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement...